News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2013

Epigenomics AG Welcomes Reimbursement for Septin9 Testing by French Insurance Provider

12.12.2013 | 131212_Epigenomics_press_release_MACSF Berlin, Germany, and U.S.A. – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, today announced that MACSF (Mutuelle d’Assurance du Corps de Santé Français), the leading French supplementary insurance provider for the medical community, will provide the blood-based Septin9 test for the early detection of colorectal […]

Read more

Epigenomics AG Announces FDA Advisory Committee Meeting to Review Epi proColon®

27.11.2013 Berlin, Germany, and U.S.A., November 27, 2013 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, today announced that the Company was informed by the U.S. Food and Drug Administration (FDA) via the premarket approval (PMA) review process for Epi proColon® that the Meeting of the Molecular and […]

Read more

Ad hoc: Epigenomics AG Announces FDA Advisory Committee Meeting to Review Epi proColon®

Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516) announces that the Company was informed by the U.S. Food and Drug Administration (FDA) via the premarket approval (PMA) review process for Epi proColon® that the Meeting of the Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee has been tentatively scheduled for Tuesday, March 25th, […]

Read more

Epigenomics’ methylated SHOX2 Biomarker shows promising results for Therapy Monitoring of Lung Cancer Patients

20.11.2013 | 131120_Press_Release_Epigenomics_SHOX2 Methylated SHOX2 allows rapid and sensitive determination of tumor response and therapy monitoring in plasma of lung cancer patients Multi-centric study with larger patient population planned for verification Further demonstrates commercial value of Epigenomics’ DNA methylation platform Berlin, Germany and U.S.A., November 20, 2013 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: […]

Read more

Epigenomics AG Announces 2013 Third Quarter and Nine Month Financial Results and Reports on Operational Highlights

06.11.2013 Berlin, Germany, and U.S.A., – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, today announced its financial results for the third quarter and the nine months ending September 30, 2013.

Read more

Ad hoc: Epigenomics AG issues EUR 500,000 in convertible bonds to Yorkville

Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516, OTC: EPGNY) announces today that the Company successfully issued convertible bonds with a nominal amount of EUR 500,000 to YA Global Master SVP Ltd. (“Yorkville”) excluding pre-emptive rights to existing shareholders. The bonds were issued at 95% of their nominal amount, carry no interest, have a term until […]

Read more